Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Ticker SymbolMREO
Company nameMereo BioPharma Group PLC
IPO dateJun 09, 2016
Founded at2015
CEODr. Denise V. Scots-Knight, Ph.D.
Number of employees36
Security typeDepository Receipt
Fiscal year-endJun 09
AddressOne Cavendish Place
CityLONDON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited Kingdom
Postal codeW1G0QF
Phone443330237300
Websitehttps://www.mereobiopharma.com/
Ticker SymbolMREO
IPO dateJun 09, 2016
Founded at2015
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data